75 related articles for article (PubMed ID: 10948322)
1. Comparative assessment of MHC antigen expression in bladder and testis tumour biopsies and established urological tumour cell lines: the relevance of cytokine and gene transfection for correction of defective MHC antigens.
Nouri AM; Symes MO
Oncol Rep; 2000; 7(5):959-64. PubMed ID: 10948322
[TBL] [Abstract][Full Text] [Related]
2. Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC.
Panelli MC; Wang E; Shen S; Schluter SF; Bernstein RM; Hersh EM; Stopeck A; Gangavalli R; Barber J; Jolly D; Akporiaye ET
Cancer Immunol Immunother; 1996 Feb; 42(2):99-107. PubMed ID: 8620527
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon gamma and tumour necrosis factor alpha treatment of tumour cells potentiates their interaction with autologous blood lymphocytes.
Vánky F; Hising C; Sjöwall K; Larsson B; Rodriguez L; Orre L; Klein E
Cancer Immunol Immunother; 1995 Oct; 41(4):217-26. PubMed ID: 7489564
[TBL] [Abstract][Full Text] [Related]
4. Selective MHC expression in tumours modulates adaptive and innate antitumour responses.
Rees RC; Mian S
Cancer Immunol Immunother; 1999 Oct; 48(7):374-81. PubMed ID: 10501850
[TBL] [Abstract][Full Text] [Related]
5. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Adair SJ; Hogan KT
Cancer Immunol Immunother; 2009 Apr; 58(4):589-601. PubMed ID: 18791715
[TBL] [Abstract][Full Text] [Related]
6. Immunological profiling of a panel of human ovarian cancer cell lines.
Carr TM; Adair SJ; Fink MJ; Hogan KT
Cancer Immunol Immunother; 2008 Jan; 57(1):31-42. PubMed ID: 17579858
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.
Qiu G; Goodchild J; Humphreys RE; Xu M
Cancer Immunol Immunother; 1999 Dec; 48(9):499-506. PubMed ID: 10602887
[TBL] [Abstract][Full Text] [Related]
8. The loss of class II MHC antigen expression by ras-transformed murine fibroblasts passaged as tumours correlates with increased tumorigenicity but is not mediated by T cells.
Morris AG; Darley RL; Bateman WJ
Cancer Immunol Immunother; 1992; 35(1):46-52. PubMed ID: 1611622
[TBL] [Abstract][Full Text] [Related]
9. Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicity.
Hacker UT; Schildhauer I; Barroso MC; Kofler DM; Gerner FM; Mysliwietz J; Buening H; Hallek M; King SB
Cancer Immunol Immunother; 2006 May; 55(5):547-57. PubMed ID: 16044254
[TBL] [Abstract][Full Text] [Related]
10. Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells.
Vánky F; Stuber G; Rotstein S; Klein E
Cancer Immunol Immunother; 1989; 28(1):17-21. PubMed ID: 2462466
[TBL] [Abstract][Full Text] [Related]
11. Sequential changes in MHC antigen expression induced by the v-Ki-ras oncogene.
Darley RL; Morris AG
Cancer Immunol Immunother; 1993 Nov; 37(6):361-6. PubMed ID: 8242660
[TBL] [Abstract][Full Text] [Related]
12. Human retinoblastoma: in vitro differentiation and immunoglobulin superfamily antigen modulation by retinoic acid.
Conway RM; Madigan MC; King NJ; Billson FA; Penfold PL
Cancer Immunol Immunother; 1997 Jun; 44(4):189-96. PubMed ID: 9222276
[TBL] [Abstract][Full Text] [Related]
13. Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin.
Steerenberg PA; De Jong WH; Geerse E; Aleva BJ; Besselink CM; Van Rens BT; Rutten VP; Poels LG; Scheper RJ; Den Otter W
Cancer Immunol Immunother; 1990; 32(2):95-104. PubMed ID: 1963114
[TBL] [Abstract][Full Text] [Related]
14. Analysis of HLA expression in human tumor tissues.
Cabrera T; López-Nevot MA; Gaforio JJ; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2003 Jan; 52(1):1-9. PubMed ID: 12536234
[TBL] [Abstract][Full Text] [Related]
15. HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.
Mendez R; Aptsiauri N; Del Campo A; Maleno I; Cabrera T; Ruiz-Cabello F; Garrido F; Garcia-Lora A
Cancer Immunol Immunother; 2009 Sep; 58(9):1507-15. PubMed ID: 19340423
[TBL] [Abstract][Full Text] [Related]
16. Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens.
Bakela K; Athanassakis I
Immunology; 2018 Mar; 153(3):315-324. PubMed ID: 29159903
[TBL] [Abstract][Full Text] [Related]
17. Proto-oncogene PML enhances antigen presentation by MHC class I molecules in human lung cancer cells.
Chang SK; Park B; Shin J; Ahn JH; Kim IH; Ahn K
Mol Cells; 2002 Aug; 14(1):130-5. PubMed ID: 12243342
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological effect of intravesical interleukin-2 on superficial bladder cancer.
Nouri AM; Hyde R; Oliver RT
Cancer Immunol Immunother; 1994 Jul; 39(1):68-70. PubMed ID: 8044829
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas.
Végh Z; Wang P; Vánky F; Hising C; Sjöwall K; Larsson B; Klein E
Cancer Immunol Immunother; 1994 Jan; 38(1):71-3. PubMed ID: 8299122
[TBL] [Abstract][Full Text] [Related]
20. Correlation between classification of human urothelial cell lines and HLA-A,B,C expression.
Ottesen SS; Tromholt V; Kieler J
Cancer Immunol Immunother; 1988; 26(1):83-6. PubMed ID: 3278802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
